Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. director-associated investment entities reported open-market sales of an aggregate 407,574 shares of Common Stock in three transactions. The sales occurred on May 8, May 11, and May 12 at weighted average prices of $0.70, $0.67, and $0.64 per share, respectively. After these transactions, entities associated with Luke Evnin collectively held 1,171,175 shares indirectly. The filing notes the trades were effected under a pre-established Rule 10b5-1 trading plan, indicating they were pre-planned rather than discretionary.
Werewolf Therapeutics, Inc. insider affiliates of RA Capital reported open-market sales of an aggregate 565,167 shares of Common Stock of HOWL. The trades occurred on May 8, 11 and 12, 2026 at weighted average prices around $0.64 per share, with detailed ranges from $0.62 to $0.76 disclosed.
The shares were sold indirectly through RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., with RA Capital Management, L.P. acting as investment manager. Following the latest transactions, one account held 406,282 shares and another held 5,709,858 shares of Common Stock indirectly. The Adviser, its general partner and related individuals disclaim beneficial ownership except to the extent of any pecuniary interest.
Werewolf Therapeutics director Luke Evnin reported indirect open-market sales of the company’s common stock by affiliated investment funds. Over May 5–7, 2026, entities including MPM Asset Management LLC and MPM BioVentures 2014, L.P. sold a total of 100,581 shares at weighted average prices around $0.63–$0.69 per share under a pre‑established Rule 10b5-1 plan dated March 26, 2026. After these transactions, the affiliated entities collectively hold 1,578,749 shares of Werewolf Therapeutics common stock, reported as indirect holdings. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Werewolf Therapeutics reported a Q1 2026 net loss of $13.5 million, or $0.28 per share. Operating expenses fell to $13.3 million from $18.0 million a year earlier, driven mainly by lower R&D spending. Cash and cash equivalents were $46.5 million as of March 31, 2026, with $10.6 million used in operating activities during the quarter.
The company adopted a 2026 restructuring plan, cutting 64% of its workforce and recording $4.3 million of related charges. Management discloses substantial doubt about its ability to continue as a going concern without additional financing or strategic transactions.
After quarter-end, Werewolf sold its JZP898 program to Jazz Pharmaceuticals for $21.0 million upfront plus a potential $2.0 million, repaid approximately $31.4 million outstanding under its K2 HealthVentures term loan, and agreed to terminate its headquarters lease early for a $2.7 million fee.